The transaction, announced in January, gives Mylan all global rights and assets relating to the Cold-EEZE brand, including all U.S. businesses and U.S. and international trademarks.
Cold-EEZE’s broad product roster includes lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms providing multi-symptom, daytime/nighttime, cough/congestion, sore throat and allergy relief, as well as immune support.
When announcing the acquisition, Mylan noted that Cold-EEZE’s cold remedy zinc gluconate lozenges are a leading product in the homeopathic category and have been clinically shown to shorten the duration of the common cold.
“The completion of this transaction is an important step as we continue to expand our consumer health care offerings. Cold-EEZE is now Mylan’s largest U.S. consumer health care brand and is part of a growing portfolio of over-the-counter products in the U.S.,” Mylan chief executive officer Heather Bresch said in a statement. “Mylan is committed to providing access to the medications that patients need, whether they are in front of or behind the pharmacy counter. We look forward to serving this loyal customer base and supporting this well-known brand.”
Besides Cold-EEZE, Mylan’s global OTC business includes such brands as Dona, Betadine, Saugella, ArmoLIPID, CB12, Brufen, EndWarts, Froben, Ferrograd, MidNite and Vivarin.